文 | 氨基观察近两年的吉利德,一直在水逆。除了长效HIV疗法,几乎没有什么好消息,尤其是在吉利德持续加大布局的抗肿瘤领域,甚至可以说是越努力越失望。不仅在TIGIT这些布局上吃尽苦头,今年以来,Trodelvy临床接连失利,导致收购Immunomedics的210亿美元巨资大概率难以收回,在CD47领域49亿美元的投资更是血本无归。当然,即使交过了巨额学费,吉利德仍然再为增长而战,活跃在肿瘤BD...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.